Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.
3.
4.

Immunoeffector and immunoregulatory activities of vasoactive intestinal peptide.

Voice JK, Dorsam G, Chan RC, Grinninger C, Kong Y, Goetzl EJ.

Regul Pept. 2002 Nov 15;109(1-3):199-208. Review.

PMID:
12409234
5.

Role of vasoactive intestinal peptide in inflammation and autoimmunity.

Gonzalez-Rey E, Delgado M.

Curr Opin Investig Drugs. 2005 Nov;6(11):1116-23. Review.

PMID:
16312132
6.

Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator.

Gonzalez-Rey E, Varela N, Chorny A, Delgado M.

Curr Pharm Des. 2007;13(11):1113-39. Review.

PMID:
17430175
7.

The role of plasmacytoid dendritic cell-derived IFN alpha in antiviral immunity.

Szabo G, Dolganiuc A.

Crit Rev Immunol. 2008;28(1):61-94. Review.

PMID:
18298384
8.

Approaches to the pharmacological modulation of plasmacytoid dendritic cells.

Fabricius D, Jahrsdörfer B.

Endocr Metab Immune Disord Drug Targets. 2011 Jun;11(2):154-64. Review.

PMID:
21476966
9.
10.

The significance of vasoactive intestinal polypeptide (VIP) in immunomodulation.

Bellinger DL, Lorton D, Brouxhon S, Felten S, Felten DL.

Adv Neuroimmunol. 1996;6(1):5-27. Review.

PMID:
8790778
11.

Cardioprotective role of the VIP signaling system.

Dvoráková MC.

Drug News Perspect. 2005 Jul-Aug;18(6):387-91. Review.

PMID:
16247516
12.

Selectivity of effects of vasoactive intestinal peptide on macrophages and lymphocytes in compartmental immune responses.

Goetzl EJ, Pankhaniya RR, Gaufo GO, Mu Y, Xia M, Sreedharan SP.

Ann N Y Acad Sci. 1998 May 1;840:540-50. Review.

PMID:
9629281
13.

Role of natural interferon-alpha producing cells (plasmacytoid dendritic cells) in autoimmunity.

Rönnblom L, Eloranta ML, Alm GV.

Autoimmunity. 2003 Dec;36(8):463-72. Review.

PMID:
14984023
14.

VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins.

Couvineau A, Laburthe M.

Br J Pharmacol. 2012 May;166(1):42-50. doi: 10.1111/j.1476-5381.2011.01676.x. Review.

15.

Novel concepts of neuropeptide-based drug therapy: vasoactive intestinal polypeptide and its receptors.

Groneberg DA, Rabe KF, Fischer A.

Eur J Pharmacol. 2006 Mar 8;533(1-3):182-94. Epub 2006 Feb 10. Review.

PMID:
16473346
16.

Colonic vasoactive intestinal polypeptide in ulcerative colitis.

Surrenti C, Renzi D, Garcea MR, Surrenti E, Salvadori G.

J Physiol Paris. 1993;87(5):307-11. Review.

PMID:
8298608
17.

Activation of plasmacytoid dendritic cells.

Fuchsberger M, Hochrein H, O'Keeffe M.

Immunol Cell Biol. 2005 Oct;83(5):571-7. Review.

PMID:
16174109
18.

Expression of vasoactive intestinal peptide in lymphocytes: a possible endogenous role in the regulation of the immune system.

Leceta J, Martínez C, Delgado M, Garrido E, Gomariz RP.

Adv Neuroimmunol. 1996;6(1):29-36. Review.

PMID:
8790779
19.

VIP modulation of immune cell functions.

De la Fuente M, Delgado M, Gomariz RP.

Adv Neuroimmunol. 1996;6(1):75-91. Review.

PMID:
8790783
20.

Immunology of VIP: a review and therapeutical perspectives.

Gomariz RP, Martinez C, Abad C, Leceta J, Delgado M.

Curr Pharm Des. 2001 Jan;7(2):89-111. Review.

PMID:
11172702

Supplemental Content

Support Center